PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort

7.1 Healthy Controls (HC) Note: Active Healthy controls previously enrolled in PPMI do not require re-assessment of eligibility criteria listed below for enrollment in PPMI Clinical. Active participants do need to be able to provide informed consent for PPMI Clinical participation (includes use of a designated research proxy). 7.1.1 Inclusion Criteria (HC) 1. Male or female age 57 years or older at Screening visit. 2. Individuals taking any of the following drugs: alpha methyldopa, methylphenidate, amphetamine derivatives or modafinil, must be willing and medically able to hold the medication for at least 5 half-lives before SPECT imaging. 3. Confirmation that participant is eligible based on Screening SPECT imaging. 4. Able to provide informed consent. 5. Either is male, or is female and meets additional criteria below, as applicable: * Female of childbearing potential who is not pregnant, lactating, or planning pregnancy during the study and has a negative pregnancy test on day of Screening SPECT imaging test prior to injection of DaTscanTM. 7.1.2 Exclusion Criteria (HC) 1. First degree relative with PD (i.e., biologic parent, sibling, child). 2. Current or active clinically significant neurological disorder (in the opinion of the Investigator). 3. Previously obtained MRI scan with evidence of clinically significant neurological disorder (in the opinion of the Investigator). 4. Received any of the following drugs: dopamine receptor blockers (neuroleptics), metoclopramide and reserpine within 6 months of Screening visit. 5. Current treatment with anticoagulants (e.g., coumadin, heparin, oral thrombin inhibitors) that might preclude safe completion of the lumbar puncture. 6. Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant coagulopathy or thrombocytopenia. 7. Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation. 8. Any other reason that, in the opinion of the investigator, would render the participant unsuitable for study enrollment. 7.2 Parkinson's Disease (PD) Note: Active PD participants previously enrolled in PPMI do not require re-assessment of eligibility criteria listed below for enrollment in PPMI Clinical. Active participants do need to be able to provide informed consent for PPMI Clinical participation (includes use of a designated research proxy). 7.2.1 Inclusion Criteria (PD) 1. Male or female age 30 years or older at Screening Visit. 2. A diagnosis of Parkinson's disease for 2 years or less at Screening Visit. 3. Not expected to require PD medication within at least 6 months from Baseline. 4. Patients must have at least two of the following: resting tremor, bradykinesia, rigidity (must have either resting tremor or bradykinesia); OR either asymmetric resting tremor or asymmetric bradykinesia. 5. Hoehn and Yahr stage I or II at Baseline. 6. Individuals taking any of the following drugs: alpha methyldopa, methylphenidate, amphetamine derivatives or modafinil, must be willing and medically able to hold the medication for at least 5 half-lives before SPECT imaging. 7. Confirmation that participant is eligible based on Screening SPECT imaging. 8. Able to provide informed consent. 9. Either is male, or is female and meets additional criteria below, as applicable: * Female of childbearing potential who is not pregnant, lactating, or planning pregnancy during the study and has a negative pregnancy test on day of Screening SPECT imaging test prior to injection of DaTscanTM. 7.2.2 Exclusion Criteria (PD) 1. Currently taking levodopa, dopamine agonists, MAO-B inhibitors, amantadine or another PD medication, except for low-dose treatment of restless leg syndrome (with permission of medical monitor). 2. Has taken levodopa, dopamine agonists, MAO-B inhibitors or amantadine within 60 days of Baseline visit. 3. Has taken levodopa or dopamine agonists prior to Baseline visit for more than a total of 90 days. 4. Atypical PD syndromes due to either drugs (e.g., metoclopramide, flunarizine, neuroleptics) or metabolic disorders (e.g., Wilson's disease), encephalitis, or degenerative diseases (e.g., progressive supranuclear palsy). 5. A clinical diagnosis of dementia as determined by the investigator. 6. Previously obtained MRI scan with evidence of clinically significant neurological disorder (in the opinion of the Investigator). 7. Received any of the following drugs: dopamine receptor blockers (neuroleptics), metoclopramide and reserpine within 6 months of Screening visit. 8. Current treatment with anticoagulants (e.g., coumadin, heparin, oral thrombin inhibitors) that might preclude safe completion of the lumbar puncture. 9. Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant coagulopathy or thrombocytopenia. 10. Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation. 11. Any other reason that, in the opinion of the investigator, would render the participant unsuitable for study enrollment. 7.3 Parkinson's Disease (PD) with LRRK2 or GBA variant Note: Active PD participants previously enrolled in PPMI do not require re-assessment of eligibility criteria listed below for enrollment in PPMI Clinical. Active participants do need to be able to provide informed consent for PPMI Clinical participation (includes use of a designated research proxy). 7.3.1 Inclusion Criteria (PD ¬- LRRK2 or GBA) 1. Male or female age 30 years or older at Screening Visit. 2. A diagnosis of Parkinson's disease for 2 years or less at Screening Visit. 3. Patients must have at least two of the following: resting tremor, bradykinesia, rigidity (must have either resting tremor or bradykinesia); OR either asymmetric resting tremor